AHF slams US House Republicans for retreat on Global AIDS Fund

17 February 2011

The USA-based AIDS Healthcare Foundation (AHF), which provides AIDS medical care and services to more than 152,000 individuals in 26 countries worldwide, has strongly condemned a move by House Republicans who, last Friday proposed slashing President Obama’s 2011 funding for global AIDS programs by $813 million.

The Republican action (affecting last year’s budget, not the fiscal year 2012 budget released Monday), if successful, would cut $450 million from the USA’s contribution to the Global Fund to Fight AIDS, Tuberculosis and Malaria as well as $363 million from additional bilateral programs including former President George W Bush’s landmark President’s Emergency Plan for AIDS Relief (PEPFAR), the successful US global AIDS program. PEPFAR claims 3.2 million people with HIV/AIDS are currently on lifesaving antiretroviral treatment as a result of its programs around the world. These Republican funding cuts represent at least 1.8 million lives that would be lost, based on PEPFAR’s per patient treatment cost of approximately $436 per patient, per year, the AHF argues.

Short-sighted cuts

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical